IL157208A0 - 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical - Google Patents

4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical

Info

Publication number: IL157208A0
Authority: IL; Israel
Prior art keywords: indan; fluoro; benzamide; pharmaceutical; synthase
Prior art date: 2001-02-13

Application number

IL15720802A

Other languages

English (en)

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-13

Filing date

2002-02-12

Publication date

2004-02-19

2002-02-12 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2004-02-19 Publication of IL157208A0 publication Critical patent/IL157208A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL15720802A 2001-02-13 2002-02-12 4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical IL157208A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP01102852		2001-02-13
PCT/EP2002/001443 WO2002064146A1 (en)	2001-02-13	2002-02-12	4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical

Publications (1)

Publication Number	Publication Date
IL157208A0 true IL157208A0 (en)	2004-02-19

Family

ID=8176423

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL15720802A IL157208A0 (en)	2001-02-13	2002-02-12	4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
IL157208A IL157208A (en)	2001-02-13	2003-08-03	4-Fluoro-N-indene-2-ilbenzamide and its use in the manufacture of drugs

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL157208A IL157208A (en)	2001-02-13	2003-08-03	4-Fluoro-N-indene-2-ilbenzamide and its use in the manufacture of drugs

Country Status (33)

Country	Link
US (3)	US6617359B2 (es)
EP (1)	EP1361882B1 (es)
JP (1)	JP4317689B2 (es)
KR (1)	KR101017531B1 (es)
CN (1)	CN100553631C (es)
AT (1)	ATE344669T1 (es)
AU (1)	AU2002253009B2 (es)
BG (1)	BG66065B1 (es)
BR (1)	BR0207178A (es)
CA (1)	CA2437966C (es)
CY (1)	CY1106278T1 (es)
CZ (1)	CZ20032154A3 (es)
DE (1)	DE60215919T2 (es)
DK (1)	DK1361882T3 (es)
EE (1)	EE05302B1 (es)
ES (1)	ES2274025T3 (es)
HR (1)	HRP20030646A2 (es)
HU (1)	HUP0302845A3 (es)
IL (2)	IL157208A0 (es)
MX (1)	MXPA03006841A (es)
MY (1)	MY135778A (es)
NO (1)	NO333522B1 (es)
NZ (1)	NZ527469A (es)
PE (1)	PE20020884A1 (es)
PL (1)	PL363452A1 (es)
PT (1)	PT1361882E (es)
RS (1)	RS51645B (es)
RU (1)	RU2308946C2 (es)
SI (1)	SI1361882T1 (es)
SK (1)	SK286513B6 (es)
TW (1)	TWI241190B (es)
WO (1)	WO2002064146A1 (es)
ZA (1)	ZA200305412B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY136316A (en) *	2001-02-13	2008-09-30	Sanofi Aventis Deutschland	Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
TWI243164B (en) *	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) *	2001-02-13	2005-10-11	Aventis Pharma Gmbh	4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US7105513B2 (en) *	2002-08-07	2006-09-12	Sanofi-Avertis Deutschland Gmbh	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1388342A1 (en) *	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7186735B2 (en)	2002-08-07	2007-03-06	Sanofi-Aventis Deutschland Gmbh	Acylated arylcycloalkylamines and their use as pharmaceuticals
EP1388341A1 (en) *	2002-08-07	2004-02-11	Aventis Pharma Deutschland GmbH	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7338956B2 (en)	2002-08-07	2008-03-04	Sanofi-Aventis Deutschland Gmbh	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
HRP20050336B1 (hr)	2002-10-21	2013-06-30	Janssen Pharmaceutica N.V.	Supstituirani tetralini i indani i njihova primjena
EP1581510A4 (en) *	2002-11-22	2006-08-30	Bristol Myers Squibb Co	1-ARYL-2-HYDROXYETHYLAMIDEALS CALIUM CHANNEL OPENER
US7132536B2 (en) *	2003-04-24	2006-11-07	Sanofi-Aventis Deutschland Gmbh	Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
DE602004011348T2 (de) *	2003-07-03	2009-01-08	Eli Lilly And Co., Indianapolis	Indanderivate als muscarinrezeptoragonisten
WO2005018620A2 (en) *	2003-08-26	2005-03-03	Cell Center Cologne Gmbh	Use of nitric oxide synthase (nos) cofactor for the treatment of sexual dysfunction
EP1529525A1 (en) *	2003-11-06	2005-05-11	Aventis Pharma Deutschland GmbH	ENOS transcription enhancers for use in the cell therapy of ischemic heart diseases
US8309608B2 (en) *	2003-11-06	2012-11-13	Sanofi-Aventis Deutschland Gmbh	Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
WO2005049000A2 (en)	2003-11-17	2005-06-02	Biomarin Pharmaceutical Inc.	Treatment of phenylketonurias with bh4
AR048931A1 (es)	2004-04-21	2006-06-14	Janssen Pharmaceutica Nv	Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
WO2006055511A2 (en) *	2004-11-17	2006-05-26	Biomarin Pharmaceutical Inc.	Stable tablet formulation of tetrahydrobiopterin
WO2006055833A2 (en) *	2004-11-19	2006-05-26	Children's Hospital Medical Center	Gtpase inhibitors and use thereof for controlling platelet hyperactivity
US20060185492A1 (en)	2005-02-18	2006-08-24	Francois Chianese	Shoulder bushing for saw blades
EP1741708A1 (en)	2005-06-28	2007-01-10	Sanofi-Aventis Deutschland GmbH	Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP1741709A1 (en)	2005-06-28	2007-01-10	Sanofi-Aventis Deutschland GmbH	Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
US7795101B2 (en) *	2006-04-03	2010-09-14	United Microelectronics Corp.	Method of forming a MOS transistor
EP1905764A1 (en)	2006-09-30	2008-04-02	Sanofi-Aventis	Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
EP1923062A1 (en)	2006-11-16	2008-05-21	sanofi-aventis	Imidazo[2,1-b]thiazoles and their use as pharmaceuticals
KR101349187B1 (ko) *	2006-12-05	2014-01-10	(주)아모레퍼시픽	지방대사 이상질환의 치료 및 예방용 약학 조성물
EP1942104A1 (en)	2006-12-20	2008-07-09	sanofi-aventis	Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP1939180A1 (en)	2006-12-20	2008-07-02	sanofi-aventis	Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1939181A1 (en)	2006-12-27	2008-07-02	sanofi-aventis	Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
EP1964840A1 (en)	2007-02-28	2008-09-03	sanofi-aventis	Imidazo[1,2-a]pyridines and their use as pharmaceuticals
EP1964841A1 (en)	2007-02-28	2008-09-03	sanofi-aventis	Imidazo[1,2-a]azine and their use as pharmaceuticals
US20160169868A9 (en) *	2007-05-24	2016-06-16	Calcimedica, Inc.	Calcium channel proteins and uses thereof
RU2487710C2 (ru) *	2007-10-09	2013-07-20	Новартис Аг	Фармацевтическая композиция валсартана
RU2400825C1 (ru) *	2009-06-10	2010-09-27	Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко Федерального агентства по здравоохранению и социальному развитию"	СПОСОБ ОДНОВРЕМЕННОЙ РЕГИСТРАЦИИ Na+-ЗАВИСИМЫХ ПОТОКОВ Ca2+ И ФУНКЦИОНАЛЬНОГО СОСТОЯНИЯ ЦЕЛОГО ИЗОЛИРОВАННОГО СЕРДЦА В ЭКСПЕРИМЕНТЕ
WO2011115804A1 (en)	2010-03-17	2011-09-22	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
EP3173407A1 (en)	2010-06-30	2017-05-31	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
RU2016101964A (ru)	2010-11-09	2018-11-21	Айронвуд Фармасьютикалз, Инк.	СТИМУЛЯТОРЫ sGC
US9216178B2 (en)	2011-11-02	2015-12-22	Biomarin Pharmaceutical Inc.	Dry blend formulation of tetrahydrobiopterin
US9139564B2 (en)	2011-12-27	2015-09-22	Ironwood Pharmaceuticals, Inc.	2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
WO2014047111A1 (en)	2012-09-18	2014-03-27	Ironwood Pharmaceuticals, Inc.	Sgc stimulators
EP2897953B8 (en)	2012-09-19	2019-06-26	Cyclerion Therapeutics, Inc.	Sgc stimulators
BR112015023349A2 (pt)	2013-03-15	2017-07-18	Ironwood Pharmaceuticals Inc	composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
MX2016007522A (es)	2013-12-11	2017-12-15	Ironwood Pharmaceuticals Inc	Estimuladores de guanilato ciclasa soluble (sgc).
WO2015106268A1 (en)	2014-01-13	2015-07-16	Ironwood Pharmaceuticals, Inc.	USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
WO2016044447A1 (en)	2014-09-17	2016-03-24	Ironwood Pharmaceuticals, Inc.	Pyrazole derivatives as sgc stimulators
US20170298055A1 (en)	2014-09-17	2017-10-19	Ironwood Pharmaceuticals, Inc.	sGC STIMULATORS
JP2017527604A (ja)	2014-09-17	2017-09-21	アイアンウッドファーマシューティカルズインコーポレイテッド	ｓＧＣ刺激剤
KR20190025989A (ko)	2016-07-07	2019-03-12	아이언우드 파마슈티컬스, 인코포레이티드	sGC 자극제의 고체 형태
BR112019000290B1 (pt)	2016-07-07	2022-10-18	Cyclerion Therapeutics, Inc	Prófármacos de fósforo dos estimuladores da sgc

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5932765A (en) *	1997-05-23	1999-08-03	Merck Patent Gesellschaft Mit	Nitromethyl ketones, process for preparing them and compositions containing them
US6180597B1 (en)	1998-03-19	2001-01-30	Brigham And Women's Hospital, Inc.	Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
AU4990599A (en)	1998-07-14	2000-02-07	Brigham And Women's Hospital	Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
AUPP891299A0 (en) *	1999-02-26	1999-03-25	Fujisawa Pharmaceutical Co., Ltd.	New 6-membered cyclic compounds
WO2001091752A1 (en) *	2000-05-30	2001-12-06	Merck & Co., Inc.	Melanocortin receptor agonists
TWI243164B (en) *	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
TWI241190B (en) *	2001-02-13	2005-10-11	Aventis Pharma Gmbh	4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020856A1 (es) *	2001-02-13	2002-11-11	Aventis Pharma Gmbh	1,2,3,4-tetrahidronaftil aminas aciladas
MY136316A (en) *	2001-02-13	2008-09-30	Sanofi Aventis Deutschland	Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
US7105513B2 (en) *	2002-08-07	2006-09-12	Sanofi-Avertis Deutschland Gmbh	Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7338956B2 (en) *	2002-08-07	2008-03-04	Sanofi-Aventis Deutschland Gmbh	Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
US7186735B2 (en) *	2002-08-07	2007-03-06	Sanofi-Aventis Deutschland Gmbh	Acylated arylcycloalkylamines and their use as pharmaceuticals
US8309608B2 (en) *	2003-11-06	2012-11-13	Sanofi-Aventis Deutschland Gmbh	Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases

2002
- 2002-02-08 TW TW091102292A patent/TWI241190B/zh not_active IP Right Cessation
- 2002-02-11 MY MYPI20020481A patent/MY135778A/en unknown
- 2002-02-12 DK DK02722066T patent/DK1361882T3/da active
- 2002-02-12 ES ES02722066T patent/ES2274025T3/es not_active Expired - Lifetime
- 2002-02-12 EE EEP200300368A patent/EE05302B1/xx not_active IP Right Cessation
- 2002-02-12 IL IL15720802A patent/IL157208A0/xx unknown
- 2002-02-12 BR BR0207178-9A patent/BR0207178A/pt not_active Application Discontinuation
- 2002-02-12 SI SI200230443T patent/SI1361882T1/sl unknown
- 2002-02-12 AT AT02722066T patent/ATE344669T1/de active
- 2002-02-12 EP EP02722066A patent/EP1361882B1/en not_active Expired - Lifetime
- 2002-02-12 JP JP2002563939A patent/JP4317689B2/ja not_active Expired - Fee Related
- 2002-02-12 WO PCT/EP2002/001443 patent/WO2002064146A1/en not_active Ceased
- 2002-02-12 HR HR20030646A patent/HRP20030646A2/hr not_active Application Discontinuation
- 2002-02-12 CZ CZ20032154A patent/CZ20032154A3/cs unknown
- 2002-02-12 CN CNB028048636A patent/CN100553631C/zh not_active Expired - Fee Related
- 2002-02-12 RU RU2003127750/15A patent/RU2308946C2/ru not_active IP Right Cessation
- 2002-02-12 HU HU0302845A patent/HUP0302845A3/hu unknown
- 2002-02-12 KR KR1020037010490A patent/KR101017531B1/ko not_active Expired - Fee Related
- 2002-02-12 NZ NZ527469A patent/NZ527469A/xx not_active IP Right Cessation
- 2002-02-12 RS YU61703A patent/RS51645B/sr unknown
- 2002-02-12 PL PL02363452A patent/PL363452A1/xx not_active Application Discontinuation
- 2002-02-12 MX MXPA03006841A patent/MXPA03006841A/es active IP Right Grant
- 2002-02-12 PT PT02722066T patent/PT1361882E/pt unknown
- 2002-02-12 AU AU2002253009A patent/AU2002253009B2/en not_active Ceased
- 2002-02-12 CA CA2437966A patent/CA2437966C/en not_active Expired - Fee Related
- 2002-02-12 SK SK1011-2003A patent/SK286513B6/sk not_active IP Right Cessation
- 2002-02-12 DE DE60215919T patent/DE60215919T2/de not_active Expired - Lifetime
- 2002-02-13 PE PE2002000123A patent/PE20020884A1/es not_active Application Discontinuation
- 2002-02-13 US US10/073,330 patent/US6617359B2/en not_active Expired - Lifetime
2003
- 2003-07-14 ZA ZA200305412A patent/ZA200305412B/xx unknown
- 2003-07-15 BG BG107994A patent/BG66065B1/bg unknown
- 2003-07-22 US US10/623,775 patent/US6812253B2/en not_active Expired - Lifetime
- 2003-08-03 IL IL157208A patent/IL157208A/en not_active IP Right Cessation
- 2003-08-11 NO NO20033546A patent/NO333522B1/no not_active IP Right Cessation
2004
- 2004-08-18 US US10/920,395 patent/US7202278B2/en not_active Expired - Lifetime
2006
- 2006-12-06 CY CY20061101753T patent/CY1106278T1/el unknown

Also Published As

Publication number	Publication date
SK286513B6 (sk)	2008-12-05
US7202278B2 (en)	2007-04-10
HUP0302845A3 (en)	2005-11-28
ZA200305412B (en)	2004-09-02
SI1361882T1 (sl)	2007-02-28
EE05302B1 (et)	2010-06-15
CN1496264A (zh)	2004-05-12
PE20020884A1 (es)	2002-11-25
HRP20030646A2 (en)	2005-06-30
NZ527469A (en)	2005-04-29
US6812253B2 (en)	2004-11-02
MXPA03006841A (es)	2003-11-13
RS61703A (sr)	2006-12-15
CY1106278T1 (el)	2011-10-12
RU2308946C2 (ru)	2007-10-27
TWI241190B (en)	2005-10-11
US20030022939A1 (en)	2003-01-30
CZ20032154A3 (cs)	2004-05-12
EE200300368A (et)	2003-10-15
PT1361882E (pt)	2007-01-31
NO20033546D0 (no)	2003-08-11
NO333522B1 (no)	2013-07-01
KR20030074809A (ko)	2003-09-19
BG107994A (bg)	2004-08-31
MY135778A (en)	2008-06-30
CN100553631C (zh)	2009-10-28
KR101017531B1 (ko)	2011-02-28
NO20033546L (no)	2003-09-24
EP1361882B1 (en)	2006-11-08
HK1062140A1 (en)	2004-10-21
BR0207178A (pt)	2004-03-30
DE60215919T2 (de)	2007-05-31
RU2003127750A (ru)	2005-03-10
US20040019114A1 (en)	2004-01-29
HUP0302845A2 (hu)	2003-12-29
JP2004518713A (ja)	2004-06-24
RS51645B (sr)	2011-10-31
WO2002064146A1 (en)	2002-08-22
SK10112003A3 (sk)	2004-01-08
ES2274025T3 (es)	2007-05-16
US20050054729A1 (en)	2005-03-10
BG66065B1 (bg)	2011-01-31
JP4317689B2 (ja)	2009-08-19
CA2437966A1 (en)	2002-08-22
AU2002253009B2 (en)	2006-09-14
PL363452A1 (en)	2004-11-15
EP1361882A1 (en)	2003-11-19
CA2437966C (en)	2011-06-14
US6617359B2 (en)	2003-09-09
ATE344669T1 (de)	2006-11-15
DK1361882T3 (da)	2007-03-12
IL157208A (en)	2009-09-22
DE60215919D1 (de)	2006-12-21

Publication	Publication Date	Title
IL157208A0 (en)	2004-02-19	4-fluoro-n-indan-2-yl benzamide and its use as pharmaceutical
MXPA04009163A (es)	2004-12-07	Nuevos compuestos.
SE0001899D0 (sv)	2000-05-22	New compounds
CY1107850T1 (el)	2013-06-19	Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
SE0100569D0 (sv)	2001-02-20	New compounds
GB0105772D0 (en)	2001-04-25	Use
MXPA02007942A (es)	2004-09-10	Derivados de pirrolopirimidinona, procesos de preparacion y uso.
SE0101387D0 (sv)	2001-04-20	Novel compounds
MXPA04006051A (es)	2004-09-27	Bifenilmetil-tiazolidindionas, analogos y su uso como activadores de ppar-gamma.
UY27368A1 (es)	2003-01-31	Nuevos compuestos
ATE381537T1 (de)	2008-01-15	Formanilid-derivative als beta2-adrenorezeptor- agonisten
ECSP066314A (es)	2006-07-28	Derivados piridilo y su uso como agentes terapéuticos
TNSN06032A1 (en)	2007-10-03	Pyridazine derivatives and their use as therapeutic agents
TW200518753A (en)	2005-06-16	Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
BG106095A (bg)	2002-06-28	Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
BR0110767A (pt)	2003-02-11	Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
GEP20053510B (en)	2005-05-10	Substituted Pyrrolopyridinone Derivatives Useful as Phosphodiesterase Inhibitors
BR0209283A (pt)	2004-07-13	Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
PL357132A1 (en)	2004-07-12	Stable, nasally, orally or sublingually applicable pharmaceutical preparation
SE0102440D0 (sv)	2001-07-05	New compound
SE0004462D0 (sv)	2000-12-04	Novel method and use
AR030945A1 (es)	2003-09-03	Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
HRPK20040328B3 (en)	2006-02-28	Pharmaceutical composition comprising gamma-butyrobetaine
MY131159A (en)	2007-07-31	New pharmaceutical compositions containing epinastine and pseudoephedrine
UY27475A1 (es)	2003-06-30	Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización